Business
ENDRA Life Sciences Issued Additional U.S. and Chinese Patents for its TAEUS® System
Four newly issued patents bolster protection for TAEUS® with 46 patents issued globally New U.S. patent expands potential licensing opportunities in data
About this update from Endra Life Sciences Inc.
[{"type":"text","content":"\nFour newly issued patents bolster protection for TAEUS® with 46 patents issued globally\n\nNew U.S. patent expands potential licensing opportunities in data management\n\n ANN ARBOR, Mich.--(BUSINESS WIRE)--\nENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of four new patents, two in the U.S. and two in China. ENDRA’s intellectual property portfolio now includes 90 assets, including 46 issued patents worldwide providing protection for the TAEUS system with its novel hybrid ultrasound and thermoacoustic imaging technology. One of the newly issued U.S. patents, which protects the ability to transfer data without an internet connection, expands potential licensing opportunities for the company.\n\nThe following four patents, strengthening the TAEUS system’s proprietary position, were issued:\n\n\nU.S. Patent No. 11314617 (the “‘617 patent”), titled “Methods and Systems for Exchange of Equipment Performance Data,” is ENDRA’s first patent that protects its proprietary method and system for acquiring, analyzing, and sharing data in the cloud. Although this technology was developed for the TAEUS system, it has broad applicability within the healthcare industry and as such, represents an additional licensing opportunity. The company has filed another application to complement the ‘617 patent, which is expected to form the keystone of a patent family.\n\n\nU.S. Patent No. 11304606, titled “Method and System for Enhancing RF Energy Delivery During Thermoacoustic Imaging,” relates to optimizing the thermoacoustic energy source, a radiofrequency emitter, to provide a stronger and clearer signal that improves thermoacoustic measurements.\n\n\nChinese Patent No. ZL 2019 8 00868104 (the “‘104 patent”), titled “Method and System for Monitoring Tissue Temperature,” relates to a novel method and system for monitoring tissue temperature during surgical procedures. ENDRA expects its TAEUS system to be effective for both thermotherapy and cryotherapy procedures. The ‘104 patent is linked to its parent, U.S. Patent No. 10631734B1.\n\n\nChinese Patent No. ZL 2019 8 00859567 (the “‘567 patent”), titled “Method and System for Estimating Fractional Fat Content of an Object of Interest,” relates to a novel method for determining the fractional fat content of an object, such as a ...